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 Rheumatic heart disease (RHD) is one of the most leading 
causes of morbidity and mortality of cardiovascular disease worldwide, 
especially in the pediatric population.1 RHD occurs as a complication of 
acute rheumatic fever (ARF), in which 35% of patients diagnosed with 
ARF developed RHD after one year, and the rate increased to 51% after 
10 years.2 The incidence of ARF in children aged 5-14 years ranges 
from 300,000 – 350,000 per year, subsequently raises the incidence risk 
of RHD.3 
 Long-term consequences and sequelae of ARF may lead to 
further inflammation process contributing to valvulitis and carditis, and 
frequently causing isolated mitral regurgitation (MR - most common 
rheumatic valve abnormalities seen in children aged < 10 years), in 
which two-thirds of the population will develop mitral stenosis over 
more than 10 years due to extensive fibrosis and calcification.4 Angio-
tensin-converting enzyme (ACE) inhibitor has been well-known for its 
reverse remodeling mechanism in degenerative MR. However, its study 
on rheumatic MR is still limited, particularly in Indonesia.5 This study 
purposed to define the characteristic profile of pediatric rheumatic 




A R T I C L E I N F O A B S T R A C T
Background : ACE inhibitors through reverse remodeling mechanisms may encounter secondary LV changes due 
to rheumatic MR. Studies regarding RHD in Indonesia, however, remain limited. 
Objectives : This study purposed to define the characteristic profile of pediatric rheumatic heart disease patients 
with mitral regurgitation who received ACE inhibitors.
Methods : This descriptive observational study involved 47 pediatric RHD patients in the Pediatric Cardiology 
Outpatient Department of dr. Saiful Anwar General Hospital from November 2018 to June 2019. Patients were 
divided into the captopril group and the no captopril group. The Captopril group was defined as patients who had 
been receiving captopril for more than or equal to 12 months prior to the study. Data about demographic and 
echocardiographic parameters were analyzed.
Results: Female patients were predominant (68%), with a mean age of 12.1 years and body mass index (BMI) of 
17.2 kg/m2. The Captopril group revealed younger age, higher BMI, and longer initial time of RHD diagnosis 
compared to the no captopril group. Evaluation of LV remodeling parameters demonstrated that the captopril 
group had smaller LVIDd, lower LVMI, higher FS, and higher LVEF. LVPWd dan RWT were found to be relatively 
similar among both groups. Evaluation of MR grade revealed that the captopril group showed the lower value of 
MR VC, MR EROA, and MR regurgitant volume, as well.  
Conclusion: Pediatric rheumatic MR receiving ACE inhibitors revealed smaller LVIDd, lower LVMI, lower MR 
grade, higher FS, and higher LVEF compared to patients receiving no ACE inhibitors.
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 This was a descriptive observational study with a collection 
of clinical and echocardiographic endpoints. Data were also obtained 
from outpatient medical records at Pediatric Cardiology Outpatient 
Department – dr. Saiful Anwar General Hospital, Malang, Indonesia 
from November 2018 to June 2019. A total of 69 patients were former-
ly enrolled. However, a total of 22 patients were excluded due to 
incomplete data or showing no mitral regurgitation on echocardio-
graphic results. In brief, the inclusion criteria were aged < 18 years, 
diagnosed with RHD-MR, and has been receiving secondary prophylax-
is Benzathine penicillin G injection within at least the past 12-months. 
Exclusion criteria were: 1) within the recurrent state of ARF; 2) 
congenital heart disease; 3) mitral stenosis; 4) no adherence to ACE 
inhibitor therapy; 5) history of infective endocarditis or having vegeta-
tion in mitral leaflet; 6) signs of congestion or dehydration; 7) history 
of valve replacement; 8) incomplete data on secondary prophylaxis; 9) 
parents’ unwillingness to sign research informed consent. Patients then 
were divided into two groups: captopril (received captopril on a 
therapeutic dose of 0.3 – 0.5 mg/kg/dose t.i.d within past 12-months or 
more) and no captopril group. History taking regarding the compliance 
to ACE inhibitor was recorded via direct interview and monthly medica-
tion card. Baseline characteristics left ventricular remodeling parame-
ters. Mitral valve regurgitation severity was variable measured in this 
study. Adherence was measured using a questionnaire (Morisky 
Medication Adherence Scale-8 [MMAS-8]). Adequate adherence was 
defined as MMAS-8 >6.6
2.2. Declaration
 
 The study complied with the 1975 Declaration of Helsinki, 
and an Institutional Review Board or Local Ethical Committee approval 
was obtained in each participating subject. The aims, risks, and benefits 
of the study were explained to each participant, and they were asked to 
sign an informed consent form prior to enrollment. Participants were 
also informed that they could quit at any time during the interview 




 The grade of mitral regurgitation and left ventricular (LV) 
remodeling parameters were assessed using echocardiography. 
Echocardiography was performed by two cardiology residents under 
the supervision of a pediatric cardiologist who was experienced in RHD 
cases. Interobserver variability was calculated using Cohen’s Kappa 
index of agreement, and we found the value of 0.82, indicating a 
perfect agreement among two residents.7 We evaluated the grade of 
MR based on quantitative and semi-quantitative methods according to 
the recommendations of the European Association of Echocardiography 
for the Assessment of Valvular Regurgitation (2010), including MR 
Effective Regurgitant Orifice Area (EROA), MR Regurgitant Volume 
(MR RVol), and MR Vena Contracta (MR VC). We examine LV remodel-
ing parameters including (1) LV dimension (left ventricular internal 
diameter in diastole [LVIDd], left ventricular posterior wall thickness at 
diastole [LVPWd], interventricular septal diameter [IVSd], fractional 
shortening [FS]); (2) LV mass and geometry (LV mass, left ventricular 
mass index [LVMI], relative wall thickness [RWT]); and (3) biventricu-
lar function, such as (left ventricular ejection fraction [LVEF], tricuspid 
annular plane systolic excursion [TAPSE], and LV diastolic function.8
 
2.4. Statistical analysis
 Profile of distribution and proportion of study population 
were analyzed using descriptive statistics. Categorical variables were 
shown as frequency, cumulative frequency, 
and percentages. For continuous variables were expressed in mean and 
standard deviation (SD). All statistical analyses were performed with 
SPSS software Version 22.
3. Result 
2.3. Baseline Characteristics
 Our study population ranged from age 9 to 15 years, with a 
mean age of 12 years. There was predominantly female sex (68.1%) 
compared to male (31.9%) with a ratio of 2:1. The mean BMI of the 
sample was 17.2 kg/m2, mostly found with normal dietary status 
(57.4%). The majority of the study population was diagnosed and 
received secondary prophylaxis of benzathine penicillin-G within a 
mean time of 34 months. About 74.5% of the study population was 
receiving captopril in their monthly routine medication for at least 12 
consecutive months.
 The baseline echocardiographic parameters demonstrated 
that mean LVIDd was 4.25 cm, mean LVPWd 0.86 cm, and mean IVSd 
0.69 cm. The mean fractional shortening was 61%. The mean LVMI of 
the samples was 95 gr/m2, with a mean RWT of 0.41. Right ventricular 
systolic function expressed a normal value with a mean TAPSE of 2.1 
cm. The left ventricular systolic function of the study population was 
found normal, with a mean LVEF of 60%. Of the total population, LV 
diastolic dysfunction was expressed in 3 grades with the proportion of 
grade 1 (59.6%), grade 2 (27.6%), and grade 3 (12.8%), respectively. 
In LV geometry subcategories, the proportion of concentric remodeling 
was the highest (46.8%), followed by normal geometry, eccentric 
hypertrophy, and concentric hypertrophy (31.9%; 14.9%; 6.4%, respec-
tively). Quantitative quantification of MR demonstrated that mean MR 
VC, MR EROA, and MR Reg Volume were 0.28 cm, 0.21 cm2, and 32 
mL/beat, respectively. Qualitatively, mild MR was the most prevalent 
(83%), followed by moderate and severe MR (10.6% and 6.4%, respec-
tively). Baseline and echocardiographic characteristics of the study 
population were shown in Table 1. 
 The sample population was furthermore classified into two 
groups, i.e., captopril and no captopril group. Female sex was seen to be 
predominant in both groups compared to male. The distribution of 
clinical and echocardiographic profiles among both groups was statisti-
cally analyzed to measure the dispersion and proportion without 
defining a cause-effect relationship (as shown in table 2). Captopril 
group demonstrated lower mean LVIDd (4.18 cm vs. 4.3 cm), higher 
mean IVSd (0.7 cm vs. 0.67 cm), higher mean LV fractional shortening 
(62% vs. 60%), lower mean LVMI (84 g/m2 and 88 g/m2, respective-
ly), and higher mean LVEF (61% vs. 58%). Mean LVPWd, mean RWT 
and mean TAPSE among both groups were found to be similar (0.86 
cm, 0.41, and 2.1 cm, respectively). The proportion of LV concentric 
remodeling was the highest in both groups compared to other LV 
geometry phenotypes (45.7% in captopril and 50% in no captopril 
group). LV normal geometry was the second-most prevalent LV geome-
try in both groups (31.4% in captopril and 33.3% in no captopril 
group). LV eccentric hypertrophy is the next common with the propor-
tion of 14.3% in the captopril and 16.7% in the no captopril group. LV 
concentric hypertrophy was only expressed in the captopril group 
(8.6%). LV diastolic dysfunction grade 1 was the most prevalent in both 
groups (e.g., 57.1% in the captopril group and 66.7% in the no 
captopril group). Subsequently, LV diastolic dysfunction grade 2 was 
found in 25.7% of the captopril group and 33.3% of the no captopril 
group. LV diastolic dysfunction grade 3 was the least prevalent with the 
proportion of 17.2% only in the captopril group. 
 Mild mitral regurgitation was the most prevalent grade of 
MR in both groups (82.8% in captopril and 83.3% in no captopril 
group) qualitatively. Moderate MR was the second most, with the 
proportion of 8.6% in the captopril and 16.7% in the no captopril 
group, respectively. Severe MR was found in the captopril
10
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group (8.6%) as compared to none in the no captopril group. This may 
explain through the mandatory use of captopril as anti-remodeling 
agents in patients with dilated LV with severe MR, as recommended by 
many current guidelines as well. Mild MR, in this case, may not be 
treated using captopril, based on the treating physician’s preferences.
Mean quantitative MR measurements (e.g., MR VC, MR EROA, and MR 
Regurgitant Volume) were found to be lower in the captopril group 
compared to no captopril group (0.19 cm vs. 0.34 cm; 0.18 cm vs. 0.24 
cm; 30 mL/beat vs. 32 mL/beat; respectively).
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Table 1. Baseline characteristics of patients included in this study
Variable
Baseline Characteristics
Age (year) (mean ± SD)
Sex
Body Height (cm) (mean ± SD)
Body Weight (kg) (mean ± SD)
BMI (kg/m2) (mean ± SD)





LVIDd (cm) (mean ± SD)
LVPWd (cm) (mean ± SD)
IVSd (cm) (mean ± SD)
LV Mass (gr) (mean ± SD)
LVMI (gr/m2)(mean ± SD)
RWT (mean ± SD)
Left Ventricle Geometry
TAPSE (cm) (mean ± SD)
LVEF (%) (mean ± SD)
LV Diastolic Dysfunction
Fractional Shortening (%)(mean ± SD)
Quantitative MR Measurement
Grade of MR 
Male (n, %) 
Female (n, %)






Concentric Remodelling (n, %)
Concentric Hypertrophy (n, %)
Eccentric Hypertrophy (n, %)
Grade 1 (n, %)
Grade 2 (n, %)
Grade 3 (n, %)
MR Vena Contracta (cm) (mean ± SD)
MR EROA (cm2) (mean ± SD)






































  3 (6.4%)
Note, data were presented in mean ± SD or n(%); BMI = body mass index; EROA = effective regurgitant orifice area; IVSd = interventricular septal diameter; LV 
= left ventricular; LVIDd = left ventricular internal diameter in diastole; LVMI = left ventricular mass index; LVPWd = left ventricular posterior wall thickness at 
diastole; MR = mitral regurgitation; RHD = rheumatic heart disease; RVol = regurgitant volume; RWT = relative wall thickness; SD = standard deviation; TAPSE 
= tricuspid annular plane systolic excursion.
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Table 2. Baseline characteristics of patients included in this study
Variable
Baseline Characteristics
Age (year) (mean ± SD)
Sex
Body Height (cm) (mean ± SD)
Body Weight (kg) (mean ± SD)
BMI (kg/m2) (mean ± SD)
Time of RHD diagnosis (month) (mean ± SD)
Dietary Status
Echocardiographic Parameters
LVIDd (cm) (mean ± SD)
LVPWd (cm) (mean ± SD)
IVSd (cm) (mean ± SD)
LV Mass (gr) (mean ± SD)
LVMI (gr/m2)(mean ± SD)
RWT (mean ± SD)
Left Ventricle Geometry
TAPSE (cm) (mean ± SD)
LVEF (%) (mean ± SD)
LV Diastolic Dysfunction
Fractional Shortening (%)(mean ± SD)
Quantitative MR Measurement
Grade of Mitral Regurgitation 
Male (n, %) 
Female (n, %)




Concentric Remodelling (n, %)
Concentric Hypertrophy (n, %)
Eccentric Hypertrophy (n, %)
Grade 1 (n, %)
Grade 2 (n, %)
Grade 3 (n, %)
MR Vena Contracta (cm) (mean ± SD)
MR EROA (cm2) (mean ± SD)





































Note, data were presented in mean ± SD or n(%); BMI = body mass index; EROA = effective regurgitant orifice area; IVSd = interventricular septal diameter; LV 
= left ventricular; LVIDd = left ventricular internal diameter in diastole; LVMI = left ventricular mass index; LVPWd = left ventricular posterior wall thickness at 
diastole; MR = mitral regurgitation; RHD = rheumatic heart disease; RVol = regurgitant volume; RWT = relative wall thickness; SD = standard deviation; TAPSE 



































 In this descriptive observational study, statistical analysis 
was used mainly to picture the profile of proportion, distribution, and 
behavior of the sample data using location (central tendency), disper-
sion, and shape statistics. This type of study has expressed no hypothe-
sis and conclude no cause-effect relationship as a result. The presented 
data may be further utilized in the inferential or observational analytic 
type of research.
 Baseline characteristics of the study population revealed that 
the sex proportion in RHD-MR patients was predominantly female 
(68.1%). This finding is consistent with the previous study by Lawrence 
et al. (2013) based on registries in Australia between 1997 – 2010, 
which showed that the proportion of female patients with RHD ranges 
from 65.8% to 71.1%. The mean age of our study was 12 years, and it 
was found to be similar with data from Northern Territory Australia 
that the highest ARF or RHD incidence occurred between 5-14 years 
with a mean age of 12 years.3 
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The mean BMI of our study population was 17.2% (with a range of 14 
– 21 kg/m2), with normal dietary status. This finding is in line with a 
previous study by Beaton et al. (2012), which demonstrated that 64% 
of pediatrics aged 10-12 years with definitive RHD had normal BMI 
(16.5 kg/m2).9
 Mean LVIDd was found to be lower in the captopril group 
compared to the no captopril group (4.18 cm and 4.3 cm, respectively), 
as well as in mean IVSd (0.67 cm vs. 0.7 cm). However, mean LVPWd 
was found similar among both groups. On the other hand, the mean 
fractional shortening in the captopril group was higher than the no 
captopril group (62.7% and 60.8%, respectively). Knirsch et al. (2010) 
reported significant improvement in LVIDd and LVPWd but not in IVSd 
and fractional shortening during 12-months follow-up of pediatric MR 
patients who received ACE inhibitor therapy.10 Tunaoglu et al. (2004) 
also revealed an improvement in LV dilatation and fractional shortening 
in pediatric RHD-MR patients during 20-days treatment of ACE 
inhibitor.11
 Either in captopril or in no captopril group has demonstrated 
LV concentric remodeling as the highest proportion of LV geometry 
phenotypes. Mean LVMI in the captopril group was found lower in the 
captopril group compared to the no captopril group (83,8 g/m2 and 88 
g/m2, respectively). However, mean RWT among both groups demon-
strated a similar measurement. Hence, this might be consistent with a 
previous study from Levine et al. (2006), which revealed 1-year 
treatment of ACE inhibitor in symptomatic RHD–MR patients signifi-
cantly improved LV mass.12
 Qualitative measurement of mitral regurgitation revealed 
that mild MR was the most prevalent in both groups. Quantitative 
measurement of mitral regurgitation using MR VC, MR EROA, and MR 
Regurgitant Volume was found to be lower in the captopril group, 
which supported the potential beneficial effect of captopril in improving 
MR severity. This finding was consistent with a previous study from 
Calabro et al. (1999). It was stated that treatment of ACE inhibitor in 
moderate-severe MR was associated with reduction of mitral valve 
regurgitation area (MR EROA), regurgitant volume, and regurgitant 
fraction.13 However, whether the difference in the proportion of MR 
grade in our study population may possibly cause by reverse remodel-
ing of LV (secondary MR) or due to the primary effect of ACE inhibitor 
towards valve repair (primary MR) still has to be further studied.
 Both groups demonstrated good RV systolic function. LV 
diastolic dysfunction was found in all study populations, with the 
highest proportion of grade 1. Mean LVEF was found higher in the 
captopril group (61% vs. 58%, respectively). Corresponding to lower 
LVIDd and higher fractional shortening in the captopril group as 
mentioned above, higher LVEF, which has been shown, may be second-
ary to the improvement of LV dimension and MR severity simultaneous-
ly. This finding was parallel with a previous study from Tunaoglu et al. 
(2004).11 
 Our study has several limitations. First, this was a descriptive 
observational study. Thus cause-effect relationship may not be defined. 
Second, no complete data of previous transthoracic echocardiography 
as a comparison to our current echocardiographic result. Third, it 
included a relatively small number of patients thus could not represent 
the real picture of the entire population. Fourth, adherence or compli-
ance was measured using MMAS-8, in which pill counting may emerge 
as a better alternative, particularly in vulnerable study populations.
5. Conclusion
 Patients who received ACE inhibitors for more than or equal 
to 12 consecutive months revealed lower LVIDd, smaller LVMI, higher 
IVSd, greater LVEF, and higher fractional shortening. 
Moreover, patients who received ACE inhibitors demonstrated lower 
MR VC, MR EROA, MR regurgitant volume; compared to patients who 
did not receive ACE inhibitors.
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